Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7,750 | 2 | 46.6% |
| Food and Beverage | $7,128 | 475 | 42.9% |
| Travel and Lodging | $1,642 | 5 | 9.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $100.00 | 1 | 0.6% |
| Education | $8.11 | 3 | 0.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $7,750 | 2 | $0 (2018) |
| Novo Nordisk Inc | $1,990 | 239 | $0 (2024) |
| AstraZeneca UK Limited | $1,642 | 5 | $0 (2022) |
| ABBVIE INC. | $832.34 | 36 | $0 (2024) |
| Indivior Inc. | $762.40 | 26 | $0 (2024) |
| GlaxoSmithKline, LLC. | $384.48 | 29 | $0 (2024) |
| Allergan, Inc. | $355.64 | 11 | $0 (2020) |
| Lilly USA, LLC | $319.68 | 16 | $0 (2024) |
| Axsome Therapeutics, Inc. | $263.12 | 6 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $249.99 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,237 | 66 | ABBVIE INC. ($369.87) |
| 2023 | $1,385 | 91 | AbbVie Inc. ($335.54) |
| 2022 | $2,473 | 76 | AstraZeneca UK Limited ($1,642) |
| 2021 | $656.68 | 57 | Novo Nordisk Inc ($298.41) |
| 2020 | $626.59 | 45 | Lilly USA, LLC ($207.25) |
| 2019 | $1,083 | 52 | Novo Nordisk Inc ($294.33) |
| 2018 | $1,637 | 45 | Eli Lilly and Company ($814.85) |
| 2017 | $7,529 | 54 | Eli Lilly and Company ($6,935) |
All Payment Transactions
486 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $37.75 | General |
| Category: OUD | ||||||
| 12/05/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: Opioid Use Disorder | ||||||
| 12/02/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $5.44 | General |
| Category: RESPIRATORY | ||||||
| 11/25/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $7.88 | General |
| Category: Diabetes | ||||||
| 11/15/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $13.32 | General |
| Category: Endocrinology | ||||||
| 11/13/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $7.06 | General |
| Category: Diabetes | ||||||
| 11/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: NEUROSCIENCE | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: RESPIRATORY | ||||||
| 11/05/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $7.14 | General |
| Category: Diabetes | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: RESPIRATORY | ||||||
| 10/15/2024 | Braeburn Inc. | BRIXADI (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: Opioid Use Disorder | ||||||
| 10/08/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: Endocrinology | ||||||
| 10/07/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: VACCINES | ||||||
| 10/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.16 | General |
| Category: NEUROSCIENCE | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/25/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 09/18/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: OUD | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Respiratory | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.04 | General |
| Category: Diabetes | ||||||
| 08/29/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Inflammation | ||||||
| 08/28/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $6.64 | General |
| Category: Diabetes | ||||||
| 08/15/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: VACCINES | ||||||
| 08/07/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $6.34 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) | Eli Lilly and Company | $7,750 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 45 | 4,619 | 11,125 | $615,141 | $318,207 |
| 2022 | 46 | 5,011 | 11,938 | $647,817 | $347,531 |
| 2021 | 57 | 6,585 | 15,301 | $732,097 | $414,453 |
| 2020 | 62 | 8,467 | 18,972 | $951,990 | $513,394 |
All Medicare Procedures & Services
210 procedure records from CMS Medicare Utilization — Page 8 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 82565 | Blood creatinine level | Office | 2020 | 365 | 820 | $7,380 | $4,177 | 56.6% |
| 82247 | Bilirubin level | Office | 2020 | 365 | 820 | $7,380 | $4,095 | 55.5% |
| 87640 | Detection test for staphylococcus aureus (bacteria) | Office | 2020 | 94 | 112 | $5,488 | $3,837 | 69.9% |
| 87641 | Detection test for staphylococcus aureus, methicillin resistant (mrsa bacteria) | Office | 2020 | 94 | 112 | $5,488 | $3,837 | 69.9% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2020 | 218 | 218 | $10,900 | $3,727 | 34.2% |
| 93306 | Ultrasound examination of heart including color-depicted blood flow rate, direction, and valve function | Office | 2020 | 33 | 35 | $11,340 | $3,410 | 30.1% |
| 84520 | Urea nitrogen level to assess kidney function | Office | 2020 | 365 | 819 | $5,733 | $3,218 | 56.1% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2020 | 36 | 36 | $9,792 | $3,207 | 32.7% |
| G0444 | Annual depression screening, 15 minutes | Office | 2020 | 182 | 182 | $9,100 | $3,120 | 34.3% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 131 | 322 | $5,796 | $3,094 | 53.4% |
| 87498 | Detection test for enterovirus (intestinal virus) | Office | 2020 | 75 | 83 | $4,482 | $2,826 | 63.1% |
| 87541 | Detection test for legionella pneumophila (water borne bacteria) | Office | 2020 | 75 | 83 | $4,482 | $2,826 | 63.1% |
| 87581 | Detection test for mycoplasma pneumoniae (bacteria) | Office | 2020 | 75 | 83 | $4,482 | $2,826 | 63.1% |
| 87486 | Detection test for chlamydia pneumoniae | Office | 2020 | 74 | 82 | $4,428 | $2,823 | 63.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 388 | 906 | $3,624 | $2,675 | 73.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 22 | 22 | $4,926 | $2,365 | 48.0% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2020 | 119 | 119 | $3,689 | $2,224 | 60.3% |
| 93975 | Ultrasound scan of abdominal, pelvic, and/or scrotal arterial inflow and venous outflow | Office | 2020 | 13 | 14 | $5,600 | $2,121 | 37.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 117 | 117 | $4,212 | $1,811 | 43.0% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2020 | 14 | 14 | $1,890 | $1,655 | 87.6% |
| 96132 | Neuropsychological testing evaluation by qualified health care professional, first 60 minutes | Office | 2020 | 16 | 16 | $3,200 | $1,635 | 51.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 25 | 27 | $1,790 | $1,253 | 70.0% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 20 | 20 | $2,965 | $1,243 | 41.9% |
| 87500 | Detection test for vancomycin resistance strep (vre) | Office | 2020 | 23 | 29 | $1,566 | $1,011 | 64.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 55 | 57 | $3,021 | $636.43 | 21.1% |
About Dr. Saadat Ansari, MD
Dr. Saadat Ansari, MD is a Internal Medicine healthcare provider based in Huntsville, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1861420994.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Saadat Ansari, MD has received a total of $16,627 in payments from pharmaceutical and medical device companies, with $1,237 received in 2024. These payments were reported across 486 transactions from 37 companies. The most common payment nature is "" ($7,750).
As a Medicare-enrolled provider, Ansari has provided services to 24,682 Medicare beneficiaries, totaling 57,336 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 210 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Huntsville, AL
- Active Since 06/29/2006
- Last Updated 12/06/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1861420994
Products in Payments
- VRAYLAR (Drug) $1,146
- Ozempic (Drug) $842.39
- SUBLOCADE (Drug) $634.80
- Rybelsus (Drug) $378.55
- Victoza (Drug) $302.41
- TRELEGY ELLIPTA (Drug) $298.36
- ABILIFY MAINTENA (Drug) $249.99
- XIFAXAN (Drug) $158.56
- CAPLYTA (Drug) $149.99
- QUVIVIQ (Drug) $144.74
- Auvelity (Drug) $143.04
- Dexcom G6 Transmitter (Medical Supply) $138.81
- SUBOXONE SUBLINGUAL FILM (Drug) $127.60
- FARXIGA (Drug) $124.34
- Saxenda (Drug) $122.63
- Sunosi (Drug) $120.08
- Kerendia (Drug) $114.75
- BRIXADI (Drug) $89.90
- ARISTADA (Drug) $87.17
- Wegovy (Drug) $74.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Huntsville
Dr. James Roy, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $849,153
Dr. Gaurav Aggarwala, M.d, M.D
Internal Medicine — Payments: $115,539
Dr. Kaushik Jain, Do, DO
Internal Medicine — Payments: $61,725
Jeffery Allison, M.d, M.D
Internal Medicine — Payments: $33,217
Ehab El-Bahesh, M.d, M.D
Internal Medicine — Payments: $31,265
Dr. Kun Chen, Md, Phd, MD, PHD
Internal Medicine — Payments: $24,543